Literature DB >> 17971291

The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes.

Simone M-L Smith1, Leigh A West, John R Hassell.   

Abstract

Fibroblast growth factor-18 (FGF-18) has been shown to regulate the growth plate chondrocyte proliferation, hypertrophy and cartilage vascularization necessary for endochondral ossification. The heparan sulfate proteoglycan perlecan is also critical for growth plate chondrocyte proliferation. FGF-18 null mice exhibit a skeletal dwarfism similar to that of perlecan null mice. Growth plate perlecan contains chondroitin sulfate (CS) and heparan sulfate (HS) chains and FGF-18 is known to bind to heparin and to heparan sulfate from some sources. We used cationic filtration and immunoprecipitation assays to investigate the binding of FGF-18 to perlecan purified from the growth plate and to recombinant perlecan domains expressed in COS-7 cells. FGF-18 bound to perlecan with a K(d) of 145 nM. Near saturation, approximately 103 molecules of FGF-18 bound per molecule of perlecan. At the lower concentrations used, FGF-18 bound with a K(d) of 27.8 nM. This binding was not significantly altered by chondroitinase nor heparitinase digestion of perlecan, but was substantially and significantly reduced by reduction and alkylation of the perlecan core protein. This indicates that the perlecan core protein (and not the CS nor HS chains) is involved in FGF-18 binding. FGF-18 bound equally to full-length perlecan purified from the growth plate and to recombinant domains I-III and III of perlecan. These data indicate that low affinity binding sites for FGF-18 are present in cysteine-rich regions of domain III of perlecan. FGF-18 stimulated 3H-thymidine incorporation in growth plate chondrocyte cultures derived from the lower and upper proliferating zones by 9- and 14-fold, respectively. The addition of perlecan reversed this increased incorporation in the lower proliferating chondrocytes by 74% and in the upper proliferating cells by 37%. These results suggest that perlecan can bind FGF-18 and alter the mitogenic effect of FGF-18 on growth plate chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971291      PMCID: PMC2696159          DOI: 10.1016/j.abb.2007.10.006

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  49 in total

1.  Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue.

Authors:  R W Farndale; D J Buttle; A J Barrett
Journal:  Biochim Biophys Acta       Date:  1986-09-04

2.  The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule.

Authors:  D M Noonan; A Fulle; P Valente; S Cai; E Horigan; M Sasaki; Y Yamada; J R Hassell
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

3.  Perlecan is essential for cartilage and cephalic development.

Authors:  E Arikawa-Hirasawa; H Watanabe; H Takami; J R Hassell; Y Yamada
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

4.  Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice.

Authors:  S Garofalo; M Kliger-Spatz; J L Cooke; O Wolstin; G P Lunstrum; S M Moshkovitz; W A Horton; A Yayon
Journal:  J Bone Miner Res       Date:  1999-11       Impact factor: 6.741

5.  Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors.

Authors:  Simone M-L Smith; Leigh A West; Prasanthi Govindraj; Xiuqin Zhang; David M Ornitz; John R Hassell
Journal:  Matrix Biol       Date:  2006-11-06       Impact factor: 11.583

6.  Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice.

Authors:  Zhongjun Zhou; Jianming Wang; Renhai Cao; Hiroyuki Morita; Raija Soininen; Kui Ming Chan; Baohua Liu; Yihai Cao; Karl Tryggvason
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

7.  Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor.

Authors:  D Aviezer; E Levy; M Safran; C Svahn; E Buddecke; A Schmidt; G David; I Vlodavsky; A Yayon
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

8.  Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3.

Authors:  D M Ornitz; P Leder
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

9.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

Authors:  R Shiang; L M Thompson; Y Z Zhu; D M Church; T J Fielder; M Bocian; S T Winokur; J J Wasmuth
Journal:  Cell       Date:  1994-07-29       Impact factor: 41.582

10.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  19 in total

1.  Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.

Authors:  Christine Y Chuang; Megan S Lord; James Melrose; Martin D Rees; Sarah M Knox; Craig Freeman; Renato V Iozzo; John M Whitelock
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

Review 2.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

3.  Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing.

Authors:  Moonsun Jung; Megan S Lord; Bill Cheng; J Guy Lyons; Hatem Alkhouri; J Margaret Hughes; Simon J McCarthy; Renato V Iozzo; John M Whitelock
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

Review 4.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

5.  Biomaterials that regulate growth factor activity via bioinspired interactions.

Authors:  Gregory A Hudalla; William L Murphy
Journal:  Adv Funct Mater       Date:  2011-05-24       Impact factor: 18.808

Review 6.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

Review 7.  Diverse cell signaling events modulated by perlecan.

Authors:  John M Whitelock; James Melrose; Renato V Iozzo
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

Review 8.  Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans.

Authors:  Catherine Kirn-Safran; Mary C Farach-Carson; Daniel D Carson
Journal:  Cell Mol Life Sci       Date:  2009-07-24       Impact factor: 9.261

9.  Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1.

Authors:  Nundehui Díaz-Lezama; Zhijian Wu; Elva Adán-Castro; Edith Arnold; Miguel Vázquez-Membrillo; David Arredondo-Zamarripa; Maria G Ledesma-Colunga; Bibiana Moreno-Carranza; Gonzalo Martinez de la Escalera; Peter Colosi; Carmen Clapp
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

10.  Investigating the role of FGF18 in the cultivation and osteogenic differentiation of mesenchymal stem cells.

Authors:  Eunyi Jeon; Ye-Rang Yun; Wonmo Kang; Sujin Lee; Young-Hag Koh; Young-Hyag Koh; Hae-Won Kim; Chang Kook Suh; Jun-Hyeog Jang
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.